Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid-inducible gene I (RIG-I) activator MK-4621 in patients with advanced or recurrent tumors

被引：0
|
作者：
Middleton, M. R. [1 ]
Wermke, M. [2 ]
Calvo, E. [3 ]
Chartash, E. [4 ]
Zhou, H. [4 ]
Zhao, X. [4 ]
Niewel, M. [5 ]
Dobrenkov, K. [4 ]
Moreno, V. [6 ]
机构：
[1] Univ Oxford, Oncol, Oxford, England
[2] Univ Klinikum CG Carus, UCC Early Clin Trial Unit, Dresden, Germany
[3] Hosp Fdn Jimenez Diaz, Clin Res, START Madrid FJD, Madrid, Spain
[4] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[5] Merck & Co Inc, Clin, Munich, Germany
[6] Hosp Fdn Jimenez Diaz, Med Oncol, START Madrid FJD, Madrid, Spain
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA16
引用
收藏
页数：1
相关论文
共 50 条
  • [11] An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma
    Fumihiko Kanai
    Shuntaro Obi
    Shigetoshi Fujiyama
    Shuichiro Shiina
    Hideyuki Tamai
    Hitoshi Mochizuki
    Yukihiro Koike
    Jun Imamura
    Takayoshi Yamaguchi
    Isamu Saida
    Osamu Yokosuka
    Masao Omata
    Hepatology International, 2014, 8 : 94 - 103
  • [12] An open-label, multicenter, phase I study of ATG-022 in patients with advanced/metastatic solid tumors (CLINCH).
    Bishnoi, Sarwan
    Cao, Dan
    Mendis, Shehara Ramyalini
    Coward, Jim
    Zhao, Jun
    Xie, Hui
    Zheng, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [13] Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors
    Minami, Hironobu
    Ando, Yuichi
    Ma, Brigette Buig Yue
    Lee, Jih-Hsiang
    Momota, Hiroyuki
    Fujiwara, Yutaka
    Li, Leung
    Fukino, Koichi
    Ito, Koji
    Tajima, Takeshi
    Mori, Asuka
    Lin, Chia-Chi
    CANCER SCIENCE, 2016, 107 (10) : 1477 - 1483
  • [14] Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors
    Balmana, Judith
    Tung, Nadine M.
    Isakoff, Steven J.
    Grana, Begona
    Ryan, Paula D.
    Rafi, Rezvan
    Tracy, Michael
    Winer, Eric
    Baselga, Jose
    Garber, Judy Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [15] A multicenter, open-label, phase I/II study of FN-1501 in patients with advanced solid tumors and acute myeloid leukemia.
    Al-Rajabi, Raed Moh'd Taiseer
    Richardson, Gary Edward
    Uprety, Dipesh
    Williamson, Stephen K.
    Hamid, Anis
    Baranda, Joaquina Celebre
    Mamdani, Hirva
    Lee, Yali
    Li, Chao
    Nitika
    Wei, Jiao
    Hui, Ai-Min
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [16] A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors
    Ma, Yuxiang
    Fang, Wenfeng
    Zhang, Yang
    Yang, Yunpeng
    Hong, Shaodong
    Zhao, Yuanyuan
    Tendolkar, Amol
    Chen, Lu
    Xu, Dong
    Shing, Jennifer
    Zhao, Hongyun
    Zhang, Li
    ONCOLOGIST, 2019, 24 (07) : 891 - +
  • [17] Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors
    Patel, Manish R.
    Falchook, Gerald S.
    Wang, Judy S.
    Imedio, Esteban Rodrigo
    Kumar, Sanjeev
    Miah, Kowser
    Mugundu, Ganesh M.
    Jones, Suzanne F.
    Spigel, David R.
    Hamilton, Erika P.
    TARGETED ONCOLOGY, 2025, 20 (01) : 127 - 138
  • [18] A phase I/II, open-label, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of HB0036 in patients with advanced solid tumors
    Sun, Yuping
    Yu, Jinming
    Tolcher, Anthony W.
    Albany, Costantine
    Chaudhry, Arvind
    Dang, Qi
    Ye, Leiguang
    Yang, Fang
    Liu, Baogang
    Sun, Longhua
    Tang, Jianjun
    Xu, Lei
    Zhu, Xiangyang
    Yang, Yongmin
    Yang, Yang
    Zhan, Yifan
    Li, Benke
    Hou, Kexin
    Zheng, Yang, Sr.
    Wang, Jingjing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [19] Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors.
    Patel, Manish R.
    Falchook, Gerald Steven
    Wang, Judy Sing-Zan
    Imedio, Esteban Rodrigo
    Kumar, Sanjeev
    Motlagh, Pejvack
    Miah, Kowser
    Mugundu, Ganesh M.
    Jones, Suzanne Fields
    Spigel, David R.
    Hamilton, Erika Paige
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [20] Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies
    Alexander Spira
    Aaron R. Hansen
    Wael A. Harb
    Kelly K. Curtis
    Erina Koga-Yamakawa
    Makoto Origuchi
    Zhonggai Li
    Bella Ertik
    Walid L. Shaib
    Targeted Oncology, 2021, 16 : 461 - 469
12345